History of Laurus Labs Limited

_x000D_ Incorporated in 2005, Laurus Labs Limited is involved in the manufacturing of pharmaceutical products.  _x000D_ _x000D_ In 2006, Research & Development (R&D) of the company started, and they signed their first patent application and in the next year, i.e., in 2007, the company established its first manufacturing unit. In the next year they supplied their first product to the USA followed by Europe in 2009. With in 8 years since its inception, in 2013, the company has crossed ₹10 billion in revenues and in the same year it received an approval from WHO for their Unit-I manufacturing site. In the next year, they commenced the construction of manufacturing Unit - II. _x000D_ _x000D_ In 2016, they launched their IPO and got listed on the exchanges. By 2017, the company had incorporated subsidiaries in the USA and the UK and had 3 manufacturing units in India. In the next year, they expanded their international presence by incorporating a subsidiary in Germany. _x000D_ _x000D_ As of March 2023, the company had 6 manufacturing units in Visakhapatnam in Andhra Pradesh and 1 in Hyderabad. Laurus Labs Limited have international offices located in Germany, SA, the USA and the UK. They serve their products all over India and in 62 countries worldwide. Laurus Labs Limited has more than 55 state-of-art R&D labs in India, over 90 APIs are manufactured and 322 patents filed. _x000D_

Business Segments of Laurus Labs Limited 

_x000D_ The primary business segments of the company are as follows:_x000D_

_x000D_
• Generic Formulations: Under this segment, the company offers products or services, such as Anti-retroviral (ARV), Anti-diabetic, Cardiovascular, Proton Pump Inhibitors (PPIs) and Central nervous system (CNS). The company has dedicated formulation research labs, analytical research labs and laboratory-scale clinical supply facilities. They are capable of developing various types of dosage forms. 
_x000D_

_x000D_

_x000D_
• CDMO-Synthesis: In this segment, the company provides Nutraceuticals, dietary supplements and cosmeceutical products. They also offer analytical and research services and commercial scale contract manufacturing.
_x000D_

_x000D_

_x000D_
• Bio: In this the company provides in-depth fermentation-based product development and manufacturing expertise, as a service to novel protein companies and bio-manufacturers. 
_x000D_
• Generic APIs: Laurus Labs Limited provides generic Active Pharmaceutical Ingredients (APIs) in this segment, such as Anti-retroviral (ARV), Anti-diabetic, Cardiovascular, Proton Pump Inhibitors (PPIs) and Oncology. 
_x000D_

_x000D_ As of March 31, 2023, some of the subsidiaries of Laurus Labs Limited are as follows:_x000D_

_x000D_
• Laurus Specialty Chemicals Private Limited: This wholly-owned subsidiary of Laurus Labs Limited is involved in the business of Specialty Chemicals.  
_x000D_
• Sriam Labs Private Limited: This wholly-owned subsidiary of the company is involved in the business of APIs and intermediates.    
_x000D_

_x000D_

_x000D_
• Laurus Holdings Limited, United Kingdom: This wholly-owned subsidiary of Laurus Labs Limited offers support services in the pharmaceuticals field in the UK.
_x000D_

_x000D_

Key Personalities of Laurus Labs Limited

_x000D_ Dr Satyanarayana Chava, Founder and CEO_x000D_ _x000D_ Dr Satyanarayana Chava is the Executive, Whole Time Director and the Chief Executive Officer of Laurus Labs Limited. He has been the Director of the company since January 21, 2006. Under his supervision, the company has grown immensely and established itself all over the world.